Vapotherm announces three pending U.S. patent applications

Vapotherm has announced the recent publication of three pending U.S. patent applications. Each of these applications represents significant milestones for the Company's intellectual property footprint.

Prior to the introduction of the Vapotherm high flow oxygen therapy system, providing medical gas via a nasal cannula was limited to lower flow rates. The Vapotherm system is able to substantially increase nasal cannula flow in a range such as 1 - 40 LPM.

"As our knowledge increases and we continue to innovate, we are significantly expanding our intellectual property," said David Lain, VP of Clinical Development.

The first of the Company's recent patent application publications is for the Vapotherm Patient Delivery Tube. This delivery tube enables maintenance of breathing gas temperature and humidification, while minimizing rainout. In addition, this new technology eliminates the need for heated wires within a patient breathing circuit. The second technology that is the subject of a patent application publication is the Vapotherm Low Flow Vapor Transfer Cartridge, used extensively in the neonatal and infant population. This specialized cartridge allows for optimal conditioning of gases delivered at lower flows such as 1-8 LPM.

The final announced patent application publication relates to an invention of Dr. Owen Bamford, involving the reduction of work of breathing. "This is an important invention of Dr. Bamford," said Dr. Lain. "Until the introduction of the Vapotherm technology, the concept that there is a reduction in work of breathing created when using high flow nasal cannula system, was unknown. Dr. Bamford has demonstrated that the work of breathing using high flow therapy via the Vapotherm system decreases as much as three fold. The clinical utility of the Vapotherm high flow nasal cannula to reduce work of breathing will be beneficial to patients experiencing respiratory compromise."

http://www.vtherm.com